Chlovelxy is taking a critical step forward in translating its lab‑proven transdermal joint care technology toward real‑world use by launching a new multi‑center clinical cooperation project across multiple international research institutions. Building on the encouraging half‑year laboratory findings from the 2026 mid‑year research report, this cross‑institutional collaboration aims to systematically validate the performance of the brand’s joint‑targeted transdermal formulas and penetration‑enhancing microneedle patch prototypes, laying solid groundwork for future global consumer market roll‑out.

Born from the founder’s personal battle with severe rheumatoid arthritis and lower‑limb tissue necrosis, Chlovelxy has long centered its R&D around solving unmet joint‑care needs. While in‑vitro testing and ex‑vivo skin models have demonstrated promising permeation, mechanical stability and dissolution performance for the dissolvable microneedle system, laboratory data alone cannot fully reflect how formulations behave under real human skin conditions, diverse body types, varying joint movement patterns and different user daily lifestyles. Multi‑center clinical cooperation fills this gap, bringing standardized human‑relevant observation data to the whole technical iteration process.

The multi‑center project brings together dermatology and musculoskeletal research teams from several independent research laboratories. Each participating site follows unified trial protocols, ensuring data comparability across regions and participant groups. Study participants cover adults experiencing mild to moderate joint discomfort, including morning stiffness, post‑exercise joint soreness and chronic repetitive joint strain, representing the core user groups Chlovelxy intends to serve.

One core objective of this clinical collaboration is to verify actual ingredient delivery efficiency of the microneedle transdermal system. Researchers will observe effective substance transfer through skin barriers, actual skin tolerability, local skin reaction profiles, as well as user‑reported wearing comfort when patches are applied on curved moving body areas such as knees, elbows and ankles. Researchers will also collect feedback on practical application experience, including ease of putting on, adhesion performance during daily activities and residual feeling after use. All these observations will feed back into formula and hardware optimization.

Beyond performance verification, the cooperation will focus on identifying variable factors that may affect practical usage outcomes. Individual skin thickness, skin hydration level, age difference and daily activity intensity all create performance fluctuation. Collecting multi‑site sample data helps the R&D team understand these variables, guiding future adjustments to patch size, needle array density and adhesive layer formulation. The insights will support product adaptation for different regional consumer groups across North America, Europe and Latin‑American markets.

Chlovelxy’s R&D team stresses that this clinical cooperation is an intermediate research phase, not finished product validation. The project will generate observation datasets for internal technical improvement, rather than immediate marketing proof. Safety monitoring runs through the whole study process; any skin adverse reactions will be fully recorded and analysed. If key safety or performance indicators do not meet preset standards, related prototype versions will be revised, and research progress will be appropriately postponed. The brand adheres to the principle that safety always precedes commercial launch.

Outcomes from this multi‑center cooperation will be combined with previous half‑year lab test results to update the 2026 full‑year product roadmap. Validated data will support subsequent pilot production adjustment, packaging optimisation and global market‑access preparation. For Chlovelxy, clinical cooperation is more than technical validation work. It represents the brand’s promise: every home‑use joint‑care solution should go through rigorous real‑world observation before reaching consumers, so that fewer people suffer the disabling joint pain experienced by the founder.

Moving forward, Chlovelxy will publish periodic public progress snapshots from the clinical project via its official news channel. Consumers can follow brand updates to track technology iteration progress.